NEST Scientific USA

nestscientificusa.com

NEST_Scientific_USA
NEST Scientific specializes in the research, manufacture and sales of high-quality cell culture vessels and general laboratory consumables. NEST Scientific is ISO 9001: 2008 certified; ISO 13485 certified; CE certified and FDA registered. NEST Scientific maintains a fully stocked warehouse at our Rahway, NJ location.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CYTOGENETICS MARKET IS NEW BUSINESS OPPORTUNITIES AND INVESTMENT RESEARCH REPORT BY 2026

Publicist360 | April 09, 2020

news image

Cytogenetics is a branch of biology, which correlates cytology and genetics. The correlation is used to study chromosomes and genes in cells and tissues. The study is conducted in relation to hereditary and variations in genes and number of chromosomes, which are used for the detection of genetic disorders as well as selection of precise therapies for treatment of these genetic disorders. Cytogenetics includes various techniques such as comparative genomic hybridization, fluorescence in situ hyb...

Read More

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

news image

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More

Industrial Impact

MOMA THERAPEUTICS ANNOUNCES FIVE-YEAR DISCOVERY COLLABORATION WITH ROCHE FOCUSED ON CRITICAL CANCER DEPENDENCIES

MOMA Therapeutics | January 04, 2024

news image

MOMA Therapeutics, a biotechnology company focused on identifying and targeting highly dynamic, difficult to drug targets in cancer and other diseases, is pleased to announce a strategic collaboration and licensing agreement with Roche. This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival. MOMA’s Kn...

Read More

Medical

DOVER TO ACQUIRE MANUFACTURER OF FLOW-MEASUREMENT DEVICES FOR BIOPHARMA AND SEMICONDUCTOR PRODUCTION APPLICATIONS

Dover | May 11, 2022

news image

Dover (NYSE: DOV) announced today that it has entered into a definitive agreement to acquire Malema Engineering Corporation ("Malema"), a designer and manufacturer of high-precision, mission-critical flow-measurement and control instruments serving customers in the biopharmaceutical, semiconductor, and industrial sectors. Malema will become part of the PSG business unit within Dover's Pumps & Process Solutions segment. Malema's products will expand Dover'...

Read More
news image

CYTOGENETICS MARKET IS NEW BUSINESS OPPORTUNITIES AND INVESTMENT RESEARCH REPORT BY 2026

Publicist360 | April 09, 2020

Cytogenetics is a branch of biology, which correlates cytology and genetics. The correlation is used to study chromosomes and genes in cells and tissues. The study is conducted in relation to hereditary and variations in genes and number of chromosomes, which are used for the detection of genetic disorders as well as selection of precise therapies for treatment of these genetic disorders. Cytogenetics includes various techniques such as comparative genomic hybridization, fluorescence in situ hyb...

Read More
news image

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More
news image

Industrial Impact

MOMA THERAPEUTICS ANNOUNCES FIVE-YEAR DISCOVERY COLLABORATION WITH ROCHE FOCUSED ON CRITICAL CANCER DEPENDENCIES

MOMA Therapeutics | January 04, 2024

MOMA Therapeutics, a biotechnology company focused on identifying and targeting highly dynamic, difficult to drug targets in cancer and other diseases, is pleased to announce a strategic collaboration and licensing agreement with Roche. This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival. MOMA’s Kn...

Read More
news image

Medical

DOVER TO ACQUIRE MANUFACTURER OF FLOW-MEASUREMENT DEVICES FOR BIOPHARMA AND SEMICONDUCTOR PRODUCTION APPLICATIONS

Dover | May 11, 2022

Dover (NYSE: DOV) announced today that it has entered into a definitive agreement to acquire Malema Engineering Corporation ("Malema"), a designer and manufacturer of high-precision, mission-critical flow-measurement and control instruments serving customers in the biopharmaceutical, semiconductor, and industrial sectors. Malema will become part of the PSG business unit within Dover's Pumps & Process Solutions segment. Malema's products will expand Dover'...

Read More

Resources

resource image

Cell and Gene Therapy

VIA Thaw™ automated dry thawer

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us